Free Trial
NASDAQ:BCTX

BriaCell Therapeutics 6/14/2024 Earnings Report

BriaCell Therapeutics logo
$4.46 -0.13 (-2.83%)
As of 04:00 PM Eastern

BriaCell Therapeutics EPS Results

Actual EPS
$1.65
Consensus EPS
-$8.25
Beat/Miss
Beat by +$9.90
One Year Ago EPS
N/A

BriaCell Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BriaCell Therapeutics Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

BriaCell Therapeutics' next earnings date is estimated for Friday, June 13, 2025, based on past reporting schedules.

Conference Call Resources

BriaCell Therapeutics Earnings Headlines

"I'm risking my reputation on this"
I've discovered something so significant about the 2025 crypto market that I had to put everything else aside and write a book about it. This isn't just another Bitcoin prediction – it's a complete roadmap for what I believe will be the biggest wealth-building opportunity of this decade. The evidence is so compelling, I'm doing something that probably seems insane: I'm giving away my entire book for free.
HC Wainwright Issues Negative Estimate for BCTX Earnings
BriaCell 3.07M share Secondary priced at $4.50
See More BriaCell Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BriaCell Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BriaCell Therapeutics and other key companies, straight to your email.

About BriaCell Therapeutics

BriaCell Therapeutics (NASDAQ:BCTX), a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

View BriaCell Therapeutics Profile

More Earnings Resources from MarketBeat